Search
Artelo Biosciences Inc
ARTLAdd to Watchlist
1.110USD
+0.010+0.91%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
747.04KMarket Cap
LossP/E TTM
More Details of Artelo Biosciences Inc Company
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Artelo Biosciences Inc Info
Ticker SymbolARTL
Company nameArtelo Biosciences Inc
IPO dateOct 13, 2015
CEOGorgas (Gregory D)
Number of employees6
Security typeOrdinary Share
Fiscal year-endOct 13
Address505 Lomas Santa Fe, Suite 160
CitySOLANA BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92075
Phone18589257049
Websitehttps://artelobio.com/
Ticker SymbolARTL
IPO dateOct 13, 2015
CEOGorgas (Gregory D)
Company Executives of Artelo Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.14K
-253.79%
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
210.00
-5488.57%
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
47.00
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Dr. R. Martin Emanuele, Ph.D.
Dr. R. Martin Emanuele, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Director
Independent Director
--
--
Mr. Mark E. Spring, CPA
Mr. Mark E. Spring, CPA
Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer
Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.14K
-253.79%
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
210.00
-5488.57%
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
47.00
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Dr. R. Martin Emanuele, Ph.D.
Dr. R. Martin Emanuele, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Artelo Biosciences Inc?
The top five shareholders of Artelo Biosciences Inc are: Mr. Gregory D. (Greg) Gorgas
How many institutions hold shares of Artelo Biosciences Inc (ARTL)?
As of 2026Q1, 21 institutions hold shares of Artelo Biosciences Inc, with a combined market value of approximately 34.88K, accounting for 3.72% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 10331.00.